TYRA ▲ +2.8% - Tyra Biosciences, Inc. $TYRA TYRA - Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 Tyra Biosciences rose 2.8% today ahead of a September 9 conference call where the company will present initial results from its SURF302 Phase 2 study of oral dabogratinib in intermediate-risk non-muscle-invasive bladder cancer. The announcement of upcoming clinical data typically attracts investor interest, particularly when a company is preparing to share results from a pivotal mid-stage trial. 04-SEP-2026 08:00 AM ET